EUVIMEDEUVIMED entdecken
Fall-Kontroll-Studie

Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study

Wubing Zhou

Sleep Medicine · 2025

DOI: 10.1016/j.sleep.2025.106793 ↗

Kurz gefasst

Fall-Kontroll-Studie in der Zeitschrift Sleep Medicine, 2025. Verfasst von Wubing Zhou. Beteiligte Einrichtung: Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: 13251364140@163.com. Hauptthemen laut MEDLINE: Migraine Disorders, NLR Family, Pyrin Domain-Containing 3 Protein, Sleep Initiation and Maintenance Disorders, Galectin 3. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic insomnia (CI) commonly co-occurs with chronic migraine (CM), and neuroinflammation may underlie this association. Galectin-3, a pro-inflammatory mediator, has been implicated in migraine and sleep regulation, but its role in CM-related insomnia and its link to NLRP3 inflammasome activation remain unclear. METHODS: We conducted a case-control study of 150 CM patients, categorized by CI status using ICSD-3 criteria and Pittsburgh Sleep Quality Index (PSQI). Clinical features, psychological assessments, and plasma biomarkers (Galectin-3, NLRP3, IL-1β) were measured. Logistic regression, multiple linear regression, mediation analysis, and ROC curves evaluated associations and diagnostic performance. RESULTS: Compared with CM without insomnia (CM-nCI), CM with insomnia (CM-CI) showed higher Galectin-3 (18.69 ± 2.95 vs. 13.41 ± 2.48 ng/mL), NLRP3 (6.72 ± 1.24 vs. 4.02 ± 1.14 ng/mL), and IL-1β (5.39 ± 1.27 vs. 3.71 ± 0.87 pg/mL; all P < 0.001). Galectin-3 independently predicted CI (adjusted OR = 1.393; 95 % CI: 1.153-1.681; P < 0.001). Mediation analysis indicated partial mediation by NLRP3 and IL-1β (41.4 % and 36.2 %, respectively). ROC analysis demonstrated good discrimination (AUC = 0.888; cutoff = 15.85 ng/mL; sensitivity = 84.0 %; specificity = 82.0 %). Galectin-3 correlated with PSQI, anxiety, depression, migraine impact, and inflammatory markers after adjustment (all P < 0.001). CONCLUSION: Elevated plasma Galectin-3 is strongly associated with CI in CM and shows good predictive value. Its relationship with NLRP3 and IL-1β suggests a shared neuroinflammatory pathway, highlighting Galectin-3 as a potential biomarker for risk stratification and targeted management of CM patients with insomnia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersNLR Family, Pyrin Domain-Containing 3 ProteinSleep Initiation and Maintenance DisordersGalectin 3InflammasomesHumansMaleFemaleBiomarkersAdultCase-Control StudiesMiddle AgedInterleukin-1betaBlood ProteinsGalectins

Stichwörter der Autor:innen

BiomarkersChronic insomniaChronic migraineGalectin-3NLRP3 inflammasomeNeuroinflammation

Substanzen

NLR Family, Pyrin Domain-Containing 3 ProteinBiomarkersGalectin 3InflammasomesNLRP3 protein, humanInterleukin-1betaLGALS3 protein, humanBlood ProteinsGalectins

Autor:innen und Institutionen

  • Second Hospital of Hebei Medical University, Shijiazhuang, China. Electronic address: 13251364140@163.com.

Zitieren

APA

Zhou, W. (2025). Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study. Sleep Medicine. https://doi.org/10.1016/j.sleep.2025.106793

Vancouver

Zhou W. Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study. Sleep Medicine. 2025. doi:10.1016/j.sleep.2025.106793

BibTeX
@article{Zhou2025,
  author = {Zhou, Wubing},
  title = {Plasma Galectin-3 as a potential predictor of chronic insomnia and its association with NLRP3 inflammasome activation in chronic migraine: A case-control study},
  journal = {Sleep Medicine},
  year = {2025},
  doi = {10.1016/j.sleep.2025.106793}
}
Kostenlos starten →